BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

 
• By Mandy Jackson

Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

alzheimer's disease on MRI - Image
Elenbecestat was the last BACE inhibitor left in clinical trials. • Source: Shutterstock

More from Clinical Trials

More from R&D